Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) is positioning itself at the center of a rapidly expanding market for Alzheimer's disease diagnostics.
The company recently announced that it has taken delivery of its first brain-dedicated Positron Emission Tomography (PET) scanning system for its flagship NovaScan Neuroimaging Clinics location, which is opening soon in Davie, Florida.
Alzheimer's Diagnostics Market Opportunity
The global Alzheimer's disease diagnostics market is experiencing strong growth driven by new disease-modifying therapies and the need for accurate patient screening. William Blair wrote on May 11 that the Alzheimer's treatment landscape had been rapidly changing following recent regulatory approvals for disease-modifying therapies, creating an urgent need for accurate patient screening and contributing to growth in the global Alzheimer's diagnostics market.
According to a June 15 report from Grand View Research, the global Alzheimer's disease diagnostics market was valued at US$9.2 billion in 2025 and was estimated to reach US$10.2 billion in 2026. Imaging techniques accounted for the largest share of the diagnostics market at 40.8 percent in 2025, while North America represented 47.5 percent of global revenue.
Why Grey Matters Health Stands Out
Grey Matters Health is building the first clinic in the United States dedicated exclusively to brain-only PET scanning for early Alzheimer's detection through beta-amyloid imaging. The clinic will also serve as a diagnostic tool for other neurodegenerative diseases, including frontotemporal dementia, Parkinson's disease, and Lewy body dementia.
The facility will use the U.S. FDA-cleared CareMiBrain PET Brain Scanning System, which does not require an integrated Computed Tomography component. This design delivers 25 percent less radiation exposure and uses a chair-style configuration for patient comfort. Scans for beta-amyloid plaque detection are covered by Medicare, Medicaid, and private insurance for patients aged 65 and older.
Key Investor Takeaways
- Grey Matters Health is opening the first U.S. brain-dedicated PET clinic in Davie, Florida, targeting early Alzheimer's detection.
- The CareMiBrain system offers lower radiation and insurance reimbursement starting at US$4,500 per scan.
- Two FDA-approved monoclonal antibody treatments require positive beta-amyloid scans before use, creating ongoing demand.
- Analyst price targets have already been achieved with a current Technical Rating of Strong Speculative Buy.
- The clinic is located within a one-hour drive of approximately six million people with low daily break-even volume.
- Management and insiders hold about 11 percent, while institutions own roughly 21 percent.
Unique Business Model and Technology Advantage
The company's NovaScan Neuroimaging Clinics model focuses on high-volume, brain-specific PET imaging rather than full-body systems. The CareMiBrain scanner supports both diagnostic and monitoring scans required by new Alzheimer's therapies such as Leqembi from Eisai and Biogen and Kisunla from Eli Lilly. Both treatments are covered by Medicare, Medicaid, and private insurance and require a positive beta-amyloid brain scan or spinal tap prior to initiation, followed by additional PET scans to track patient progress.
Future Market Insights reported on June 16 that precision medicine and biomarker-guided testing had continued reshaping healthcare diagnostics. Accurate biomarker testing is essential as therapies become increasingly targeted.
Industry Timing and Trends
Grand View Research noted that the growing global burden of Alzheimer's has intensified the need for early detection and precise diagnosis. Advances in genomics, proteomics, and metabolomics have expanded the use of biomarkers, while PET imaging continues to play a crucial role. Advances in image analysis and machine learning have improved the accuracy and reliability of neuroimaging.
William Blair described PET imaging as the gold standard for visualizing amyloid plaques. Increased use of amyloid-targeted therapies, together with favorable reimbursement policies, has supported demand for Alzheimer's PET imaging. Blood-based biomarker tests have emerged as cost-effective screening tools that help identify patients requiring more advanced imaging.
Analyst Views and Valuation
1In a March 26 report, analyst Stewart Thomson discussed Grey Matters Health Inc.'s Alzheimer's disease imaging strategy, highlighting the company's plans to establish a network of specialized neuroimaging clinics in the United States focused on brain-specific Positron Emission Tomography imaging. Thomson wrote that Grey Matters was pursuing a strategy centered on brain-optimized PET scans for the diagnosis of Alzheimer's disease and referenced the company's objective of targeting what it described as a CA$6.9 billion emerging market.
Thomson assigned Grey Matters a Technical Rating: Strong Speculative Buy and set price targets of CA$0.08 in the short term, CA$0.17 in the medium term, and CA$0.40 in the long term. Each of those price targets has since been achieved.
Clinic Opening and Operational Milestones
Grey Matters is continuing preparations for the opening of its first NovaScan Neuroimaging Clinics location in Davie, Florida. Preparations include securing all required licenses, completing construction, and installing technical and operational systems. The company plans to provide an update on the official clinic opening date and the timing for accepting patient referrals.
According to the company's May 2026 investor presentation, the first NovaScan Neuroimaging Clinics location is situated at the HCA Florida University Medical Office Building on the HCA Florida University Hospital campus in Davie, Florida. The location is within a one-hour drive of approximately six million people.
The investor presentation states that the CareMiBrain PET Brain Scanning System will be the first of its kind purchased for operation in the United States. The system is FDA-cleared, does not require a CT scan, provides 25 percent less radiation exposure, and scans are covered by Medicare, Medicaid, and private insurance with a stated minimum reimbursement of US$4,500 per scan.
The presentation further outlines operating metrics for a NovaScan clinic, including a maximum of 15 scans per day, an annual maximum capacity of 3,600 scans, monthly operating costs of US$70,000, and a stated break-even point of 1.6 scans per day.
Streetwise Ownership Overview*
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB)
| Strike Price | Number | Expiry Date |
|---|---|---|
| $2.4 | 340,000 | 08/01/26 |
| $2.4 | 4,480 | 08/01/26 |
| $2.4 | 196,000 | 08/19/26 |
| $2.4 | 4,000 | 08/19/26 |
| $9.38 | 114,887 | 07/04/27 |
| $10.31 | 4,338 | 07/04/27 |
| $10.31 | 8,192 | 08/22/27 |
| $10.63 | 149,560 | 08/22/27 |
| $25 | 450,000 | 05/22/30 |
| $2.5 | 550,000 | 05/22/30 |
| $15 | 517,500 | 06/30/30 |
| $15 | 116,667 | 07/24/30 |
| $1.5 | 126,429 | 11/14/30 |
| $1.5 | 150,000 | 11/28/30 |
| $1.5 | 251,786 | 12/23/30 |
| $1.5 | 83,929 | 12/31/30 |
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 04/21/26 | AGN | 10 | GREY | 1 |
| 03/03/23 | AGN | 1 | AGN | 4 |
| 11/24/21 | AGN | 100 | AGN | 1 |
| 02/19/19 | BTH | 1 | AGN | 1 |
| 10/17/18 | BTH | 2 | BTH | 1 |
Share Structure and Ownership
2Management and insiders own about 11 percent of the company, and about 21 percent is owned by institutions. The rest is with retail. Top shareholders include Alpha North Asset Management with 20.52 percent, Chief Executive Officer Christopher Moreau with 5.05 percent, Chairman of the Board Harry Bloomfield with 1.97 percent, Chief Financial Officer James Kinley with 1.4 percent, and Director Rajpaul Attariwala with 1.2 percent.
Grey Matters has 54.1 million outstanding shares, a market cap of CA$1.37 million, and a 52-week range of CA$0.035 - CA$0.10.
Common Questions from Investors
What is the CareMiBrain system, and why does it matter? It is an FDA-cleared brain-dedicated PET scanner that requires no CT component, reduces radiation exposure by 25 percent, and qualifies for insurance reimbursement starting at US$4,500 per scan.
Why are new Alzheimer's treatments driving demand for PET scans? Leqembi and Kisunla require a positive beta-amyloid scan before treatment begins and additional scans to monitor progress, creating recurring demand.
What is the break-even volume for a NovaScan clinic? The clinic breaks even at just 1.6 scans per day, while maximum capacity reaches 3,600 scans annually.
Where is the first clinic located? It is located at the HCA Florida University Medical Office Building on the HCA Florida University Hospital campus in Davie, Florida, within reach of six million people.
Has the company achieved analyst price targets? Yes, all three targets set by analyst Stewart Thomson (CA$0.08 short-term, CA$0.17 medium-term, CA$0.40 long-term) have been reached.
Grey Matters Health is executing on a focused strategy to address a clear clinical need with specialized technology and favorable reimbursement. Investors should monitor upcoming updates on the Florida clinic opening and patient referral timelines as key near-term milestones.
Important Disclosures:
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Grey Matters Health.
- Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Disclosure for the quote from the Stewart Thomson article published on March 26, 2026
- For the quoted article (published on March 26, 2026), Grey Matters Health has paid Street Smart, an affiliate of Streetwise Reports, US$3,000.
- Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
2. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
